Abstract
Materials and methods We treated 32 CH patients (8 males; 24 females; 44.76 ±11.23 mean age) with 190-units BoNTA injections. Sessions took place from January 2014 to June 2015 once every 3 months; patients received headache education; at the baseline (T0) and at the final follow-up (T1) patients completed a headache diary, pain Numerical Rating Scale (NRS), Migraine Disability Assessment (MIDAS), Zung Self-Rating Anxiety Scale (SAS) and Zung Self-Rating Depression Scale (SDS). We considered patients responders if they had > 50% reduction in headache frequency and/or pain intensity compared with baseline. Using SOFA Statistics 1.4.4 software, we calculated descriptive indicators and evaluated treatment effect using paired-samples Student’s t-test on clinical and psychosocial variables between T0 and T1. We set p < 0.05 as threshold of statistical significance.
Highlights
Type-A botulinum toxin (BoNTA) therapy has emerged as an effective treatment for chronic headache (CH) [1]
We considered patients responders if they had > 50% reduction in headache frequency and/or pain intensity compared with baseline
Our data support that BoNTA in a multidisciplinary setting is an effective treatment for chronic headache, potentially addressing pain-related affective disorders
Summary
Type-A botulinum toxin (BoNTA) therapy has emerged as an effective treatment for chronic headache (CH) [1]. No conclusive data exists about BoNTA efficacy in CH comorbid with anxiety and depression disorders. Our open prospective study aimed to evaluate CH BoNTA treatment efficacy regarding clinical and psychopathological variables in a multidisciplinary setting
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
